Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide Extension Study for Japanese SBS Patients
NCT03596164Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2018
- Primary completion
- Jan 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teduglutide in short bowel syndrome (SBS), sponsored by Takeda. Primary endpoints: Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at 40.2 months, Change From Baseline in Weekly PS Volume at 40.2 months and 9 more. Started Jul 2018; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT03596164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596164.